Non-NAD-like PARP-1 inhibitors in prostate cancer treatment-Reference-Cited by-同舟云学术

Non-NAD-like PARP-1 inhibitors in prostate cancer treatment

Published:2019-09 Issue: Volume:167 Page:149-162
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Karpova Yaroslava,Wu Chao,Divan Ali,McDonnell Mark E.,Hewlett Elizabeth,Makhov Peter,Gordon John,Ye Min,Reitz Allen B.,Childers Wayne E.,Skorski Tomasz,Kolenko Vladimir,Tulin Alexei V.

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference43 articles.

1. Cancer statistics;Siegel;CA-Cancer J. Clin.,2019

2. Molecular determinants of resistance to antiandrogen therapy;Chen;Nat. Med. (N. Y., NY, U. S.),2004

3. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

4. The hallmarks of castration-resistant prostate cancers;Katsogiannou;Cancer Treat. Rev.,2015

5. The evolution of prostate cancer therapy: targeting the androgen receptor;Aragon-Ching;Front. Oncol.,2014

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptional regulation mechanism of PARP1 and its application in disease treatment;Epigenetics & Chromatin;2024-08-08

2. Experimental evidence for Parthanatos-like mode of cell death of heat-damaged human skin fibroblasts in a cell culture-based in vitro burn model;Burns;2024-08

3. Advances in the Synthesis of Biologically Active Quaternary Ammonium Compounds;International Journal of Molecular Sciences;2024-04-24

4. Synthesis, Antitumor Activities, and Molecular Modeling of 4-Anilinoquinazoline Derivatives as EGFR-TK Inhibitors;Pharmaceutical Chemistry Journal;2023-11

5. Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities;Neurobiology of Disease;2023-10